Scientist II, DMPK

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified

Salary

Not verified not verified - source not recorded; timestamp not recorded

401(k) match

Not verified

Was this benefit information wrong? Tell us.

Market context

Median wage (BLS OEWS)

$111,944 national median

Projected growth (BLS Employment Projections)

+13.7% - Much faster than average

33% above the BLS national median for data and ml aggregate.

Matched to SOC 15-1252 - Data and ML aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Schedule

Shift type

Not verified

Weekend work

Not verified

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Scientist II, DMPK Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The DMPK Scientist will be a key member of the Drug Metabolism and Pharmacokinetics (DMPK) team within the Nonclinical Development and Clinical Pharmacology (NDCP) department. Specifically, you will: - Design and execute in vitro and in vivo metabolite identification studies using liver microsomes, hepatocytes, recombinant enzymes, and biological samples (blood, plasma, tissue, urine, bile, etc.), and perform metabolite profiling and structural elucidation. - Characterize major, unique, or disproportionate metabolites to support candidate selection, MIST (Metabolites in Safety Testing) analysis, and metabolite regulatory strategy. - Design and perform mechanistic studies to understand metabolic pathways and enzyme kinetics; work with pharmaceutical product teams to characterize drug degradation products and impurities. - Author and review DMPK sections of regulatory submissions and respond to questions from regulatory agencies. - Build and maintain strong collaborative partnerships across functional areas, e.g., Discovery research, Clinical Pharmacology, Medicinal Chemistry, Pharmaceutical Development, Toxicology,

Read the full description at www.revmed.com. FewerJobs shows a source-linked preview and links to the original posting.